Dec. 8, 2015

Researchers from the OHSU Center for Evidence-based Policy contributed Medicaid data to Senator Wyden and Grassley's investigation into Gilead Sciences' Hepatitis C drug, Sovaldi (sofosbuvir). 

The Senate report, released Dec. 1, 2015, found that the company's pricing and marketing strategy maximized revenue, making it unaffordable for many patients. 

The report received national media attention, including coverage in the Wall Street Journal, New York Times/AP and Washington Post. 

The Center for Evidence-based Policy's team contributed Medicaid Prior Authorization data to the investigation, which drew from 20,000 pages of internal company documents, dozens of interviews with health care experts and data from Medicaid programs in 50 states and the District of Columbia. View Senate media release to access full report.

The OHSU Center for Evidence-based Policy is a national leader in evidence-based decision making and policy design. It works with federal, state and local policymakers in more than 25 states to use high-quality evidence to inform decisions, improve health outcomes, and maximize value. 

Team members included: 

• Allison Leof, Ph.D. 
• Martha Gerrity, M.D., MPH, Ph.D.
• Nicole King Erika Zoller, MPH
• Ellen Fugate 
• Pam Curtis, MS
• Valerie King, M.D., MPH